Matches in SemOpenAlex for { <https://semopenalex.org/work/W2897445406> ?p ?o ?g. }
- W2897445406 endingPage "987" @default.
- W2897445406 startingPage "967" @default.
- W2897445406 abstract "In men with prostate cancer (PCa) treated with curative intent, controversy exists regarding the impact of biochemical recurrence (BCR) on oncological outcomes.To perform a systematic review of the existing literature on BCR after treatment with curative intent for nonmetastatic PCa. Objective 1 is to investigate whether oncological outcomes differ between patients with or without BCR. Objective 2 is to study which clinical factors and tumor features in patients with BCR have an independent prognostic impact on oncological outcomes.Medline, Medline In-Process, Embase, and the Cochrane Central Register of Controlled Trials were searched. For objective 1, prospective and retrospective studies comparing survival outcomes of patients with or without BCR following radical prostatectomy (RP) or radical radiotherapy (RT) were included. For objective 2, all studies with at least 100 participants and reporting on prognostic patient and tumor characteristics in patients with BCR were included. Risk-of-bias and confounding assessments were performed according to the Quality in Prognosis Studies tool. Both a narrative synthesis and a meta-analysis were undertaken.Overall, 77 studies were included for analysis, of which 14 addressed objective 1, recruiting 20 406 patients. Objective 2 was addressed by 71 studies with 29 057, 11 301, and 4272 patients undergoing RP, RT, and a mixed population (mix of patients undergoing RP or RT as primary treatment), respectively. There was a low risk of bias for study participation, confounders, and statistical analysis. For most studies, attrition bias, and prognostic and outcome measurements were not clearly reported. BCR was associated with worse survival rates, mainly in patients with short prostate-specific antigen doubling time (PSA-DT) and a high final Gleason score after RP, or a short interval to biochemical failure (IBF) after RT and a high biopsy Gleason score.BCR has an impact on survival, but this effect appears to be limited to a subgroup of patients with specific clinical risk factors. Short PSA-DT and a high final Gleason score after RP, and a short IBF after RT and a high biopsy Gleason score are the main factors that have a negative impact on survival. These factors may form the basis of new BCR risk stratification (European Association of Urology BCR Risk Groups), which needs to be validated formally.This review looks at the risk of death in men who shows rising prostate-specific antigen (PSA) in the blood test performed after curative surgery or radiotherapy. For many men, rising PSA does not mean that they are at a high risk of death from prostate cancer in the longer term. Men with PSA that rises shortly after they were treated with radiotherapy or rapidly rising PSA after surgery and a high tumor grade for both treatment modalities are at the highest risk of death. These factors may form the basis of new risk stratification (European Association of Urology biochemical recurrence Risk Groups), which needs to be validated formally." @default.
- W2897445406 created "2018-10-26" @default.
- W2897445406 creator A5002985141 @default.
- W2897445406 creator A5007980272 @default.
- W2897445406 creator A5009101766 @default.
- W2897445406 creator A5011133286 @default.
- W2897445406 creator A5013864806 @default.
- W2897445406 creator A5016345321 @default.
- W2897445406 creator A5018595176 @default.
- W2897445406 creator A5019052630 @default.
- W2897445406 creator A5019998379 @default.
- W2897445406 creator A5020731291 @default.
- W2897445406 creator A5021804435 @default.
- W2897445406 creator A5023131151 @default.
- W2897445406 creator A5030545703 @default.
- W2897445406 creator A5032518609 @default.
- W2897445406 creator A5053854071 @default.
- W2897445406 creator A5054298777 @default.
- W2897445406 creator A5055125493 @default.
- W2897445406 creator A5056479059 @default.
- W2897445406 creator A5060396380 @default.
- W2897445406 creator A5061892825 @default.
- W2897445406 creator A5063466486 @default.
- W2897445406 creator A5067177119 @default.
- W2897445406 creator A5068797509 @default.
- W2897445406 creator A5075511405 @default.
- W2897445406 creator A5075546358 @default.
- W2897445406 creator A5078216208 @default.
- W2897445406 creator A5080627838 @default.
- W2897445406 creator A5089586523 @default.
- W2897445406 date "2019-06-01" @default.
- W2897445406 modified "2023-10-18" @default.
- W2897445406 title "Prognostic Value of Biochemical Recurrence Following Treatment with Curative Intent for Prostate Cancer: A Systematic Review" @default.
- W2897445406 cites W1503328597 @default.
- W2897445406 cites W1506304343 @default.
- W2897445406 cites W1575570630 @default.
- W2897445406 cites W1724192062 @default.
- W2897445406 cites W1736848461 @default.
- W2897445406 cites W1810097221 @default.
- W2897445406 cites W1977315722 @default.
- W2897445406 cites W1980767217 @default.
- W2897445406 cites W1989530624 @default.
- W2897445406 cites W1998502341 @default.
- W2897445406 cites W2006291887 @default.
- W2897445406 cites W2008244414 @default.
- W2897445406 cites W2010787841 @default.
- W2897445406 cites W2018998854 @default.
- W2897445406 cites W2021051336 @default.
- W2897445406 cites W2023126708 @default.
- W2897445406 cites W2023392429 @default.
- W2897445406 cites W2026190552 @default.
- W2897445406 cites W2028198082 @default.
- W2897445406 cites W2030169234 @default.
- W2897445406 cites W2032361474 @default.
- W2897445406 cites W2039536878 @default.
- W2897445406 cites W2047227275 @default.
- W2897445406 cites W2053280656 @default.
- W2897445406 cites W2055357148 @default.
- W2897445406 cites W2061988762 @default.
- W2897445406 cites W2068115015 @default.
- W2897445406 cites W2071879495 @default.
- W2897445406 cites W2073988927 @default.
- W2897445406 cites W2082977560 @default.
- W2897445406 cites W2085370706 @default.
- W2897445406 cites W2085790709 @default.
- W2897445406 cites W2090722648 @default.
- W2897445406 cites W2092588053 @default.
- W2897445406 cites W2095511137 @default.
- W2897445406 cites W2096490409 @default.
- W2897445406 cites W2096600898 @default.
- W2897445406 cites W2100001148 @default.
- W2897445406 cites W2101229498 @default.
- W2897445406 cites W2107671263 @default.
- W2897445406 cites W2109199549 @default.
- W2897445406 cites W2110569728 @default.
- W2897445406 cites W2115047638 @default.
- W2897445406 cites W2119056140 @default.
- W2897445406 cites W2131317892 @default.
- W2897445406 cites W2132024289 @default.
- W2897445406 cites W2132935740 @default.
- W2897445406 cites W2135826149 @default.
- W2897445406 cites W2139654182 @default.
- W2897445406 cites W2142536161 @default.
- W2897445406 cites W2147754924 @default.
- W2897445406 cites W2150838278 @default.
- W2897445406 cites W2151114651 @default.
- W2897445406 cites W2152283043 @default.
- W2897445406 cites W2152715017 @default.
- W2897445406 cites W2161749968 @default.
- W2897445406 cites W2170025943 @default.
- W2897445406 cites W2172086979 @default.
- W2897445406 cites W2196246894 @default.
- W2897445406 cites W2199865317 @default.
- W2897445406 cites W2313181755 @default.
- W2897445406 cites W2330292521 @default.
- W2897445406 cites W2466734156 @default.
- W2897445406 cites W2487033212 @default.
- W2897445406 cites W2510755861 @default.